Refine by
Clinical Program Equipment & Supplies Near Panama
72 equipment items found
Manufactured by:Biotron Limited based inNorth Ryde, AUSTRALIA
Biotron is developing novel small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory T-cell down regulation. CD28 receptor is expressed on the surface of the majority of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A humanized monoclonal antibody, is an antagonist of the alpha chain of the interleukine-7 receptor, CD127, present on T effector cells, thus down regulating the immune activity. Interleukin-7 (IL-7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to tumor activity and responsiveness to ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous human-infective CoVs, SARS and MERS, to identify vaccine ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
Manufactured by:Aposcience AG based inVienna, AUSTRIA
Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled ...
Manufactured by:BioXcel Therapeutics, Inc. based inNew Haven, CONNECTICUT (USA)
BXCL501 is our most advanced neuroscience clinical program. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist. It is being investigated for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for agitation in Alzheimer’s disease, and as an adjunctive treatment ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor. More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research. ...
Manufactured by:Elixir Medical Corporation based inMilpitas, CALIFORNIA (USA)
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
CT-132 is under development as a clinically-validated digital program for ...
by:Oligomerix, Inc. based inWhite Plains, NEW YORK (USA)
While Alzheimer’s is the largest tauopathy, other tauopathies are rare diseases that present accelerated regulatory pathways and significant near-term commercial opportunities. These rare diseases shown in Chart A below have a tau etiology similar to AD. Oligomerix’s 1st clinical program focuses on demonstrating safety and efficacy of our lead ...
Manufactured by:MD Spiro, A MicroDirect Company based inLewiston, MAINE (USA)
The CO Check+ is an innovative smoking cessation tool designed specifically for use in smoking cessation programs and clinics. One single breath of expiration into the CO Check+ provides instant results in PPM and %COHb via the large, easy-to-read ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
Clickheart is under development as a clinically-validated digital program for acute coronary ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
CT-161 is under development as a clinically-validated digital program for overactive ...
Manufactured by:Microbion Corporation based inBozeman, MONTANA (USA)
Microbion has two Phase 2 clinical programs in diabetic foot ulcer infection and orthopedic implant infection. In addition, preclinical programs are under development for multiple therapeutic indications, including the treatment of serious respiratory ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
Clickadian is under development as a clinically-validated fully digital program for ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...